American Journal of Obstetrics & Gynecology
Volume 200, Issue 2 , Pages 170.e1-170.e7, February 2009

Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy

  • Karel Allegaert, PhD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
    • Corresponding Author InformationReprints: Karel Allegaert, PhD, Neonatal Intensive Care Unit, Department of Woman and Child, University Hospital, Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
  • ,
  • Tim van Mieghem, MD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
  • ,
  • Rene Verbesselt, PhD

      Affiliations

    • Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium
  • ,
  • Jan de Hoon, PhD

      Affiliations

    • Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium
  • ,
  • Maissa Rayyan, MD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
  • ,
  • Roland Devlieger, PhD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
  • ,
  • Jan Deprest, PhD

      Affiliations

    • Division of Woman and Child, University Hospitals Leuven, Leuven, Belgium
  • ,
  • Brian J. Anderson, PhD

      Affiliations

    • Department of Anesthesiology, University of Auckland, Auckland, New Zealand

Received 25 March 2008; received in revised form 11 July 2008; accepted 29 August 2008. published online 12 November 2008.

Objective

To study cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy.

Study Design

Newly collected time-concentrations profiles and reported studies investigating cefazolin disposition (plasma, amniotic fluid) were pooled. Nonlinear mixed effect modeling was applied. A 2-compartment linear disposition model was used to fit cefazolin plasma observations. A third compartment was used to model amniotic fluid concentration.

Results

One hundred eighty-seven plasma and 96 amniotic fluid samples were collected in 82 pregnancies (17-40 weeks gestational age). Cefazolin clearance and distribution estimates were 7.44 L/h and 12.04 L without gestational age-dependent trends in maternal plasma. The equilibration half-life (Teq) between plasma and amniotic fluid at term gestational age was 4.4 hours, increased with decreasing gestational age, and was 9.09 times longer in patients with polyhydramnios.

Conclusion

Cefazolin clearance and distribution volume are increased during pregnancy. The cefazolin Teq depends on gestational age and polyhydramnios. On the basis of these observations, dosing regimes to attain higher amniotic fluid concentrations were formulated.

Key words: amniotic fluid, cefazolin, pharmacokinetics, pregnancy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Cite this article as: Allegaert K, van Mieghem T, Verbesselt R, et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol 2009;200:170.e1-170.e7.

 Drs Allegaert and Deprest are supported by the Fonds Wetenschappelijk Onderzoek-Vlaanderen. Dr Devlieger is supported by the Clinical Research Fund of the University Hospitals, Leuven. Dr van Mieghem is supported by a Grant of the EC (EuroSTEC, LSHC-CT-2006-037409).

PII: S0002-9378(08)01036-3

doi:10.1016/j.ajog.2008.08.067

American Journal of Obstetrics & Gynecology
Volume 200, Issue 2 , Pages 170.e1-170.e7, February 2009